期刊文献+

卵巢癌患者的免疫功能探讨 被引量:16

Analysis of Immune Function in Patient with Ovarian Cancer
下载PDF
导出
摘要 目的分析卵巢癌患者外周血T淋巴细胞亚群、免疫球蛋白的变化,监测卵巢癌患者的免疫功能水平。方法用流式细胞仪测定45例卵巢癌患者、35例卵巢良性肿瘤患者和30名健康对照组的外周血T淋巴细胞亚群,采用免疫比浊法测定3组样本血清Ig A、Ig G、Ig M含量。结果卵巢癌患者全血CD8+明显高于健康对照组(P<0.05),而血CD4+及CD4+/CD8+比值则显著低于健康对照组(P<0.05)。Ig G、Ig M水平均高于对照组(P<0.05),而Ig A水平两组无显著差异(P>0.05)。外周血T淋巴细胞亚群和免疫球蛋白的改变与卵巢癌病理分期有关,分期越晚,CD4+及CD4+/CD8+比值越低,CD8+、Ig G、Ig M水平越高,Ⅱ期与Ⅲ期、Ⅳ期之间有显著性差异(P<0.05)。结论卵巢癌患者细胞免疫功能降低,体液免疫功能增强。外周血T细胞亚群和免疫球蛋白的检测对判断卵巢癌患者的病情、预后以及机体的免疫功能的判断有一定意义。 Objective To evaluate the alternation of peripheral blood T-lymphocyte cell subsets and immunoglobulin and investigate the diagnostic value of them in patients with ovarian cancer. Methods Peripheral blood samples were collected from the 45 ovarian cancer,30 healthy people and 35 benign ovarian disease patients,the level of T-Lymphocyte subsets were detected by Beckman Coulter-EPICS-XL Flow Cytometry( FCM),and the level of Ig A,Ig G and Ig M were detected by the immunoturbidimetric assay. Results The percentages of T-lymphocyte subsets CD8+in ovarian cancer patients were higher than those in control groups( P 〈 0. 05). The percentages of T-lymphocyte subsets CD4+and the ratio of CD4+/ CD8+in ovarian cancer patients were significantly lower than those in control groups( P 〈 0. 05). The concentrations of Ig G and Ig M in ovarian cancer groups were higher than those in control( P 〈 0. 05). The concentrations of Ig A were not significantly different between those groups( P 〉 0. 05). The changes of peripheral blood T lymphocyte subsets and immunoglobulin of ovarian cancers were related to pathological stages. The more later of pathological stage,the lower of CD4 + and CD4 + / CD8 + ratio,and the more higher of CD8 +,Ig G and Ig M level. There was significantly difference between stage Ⅱwith stage Ⅲ and IV( P 〈 0. 05). Conclusion The cellular immunity function of ovarian cancer patients is decreased,and humeral immunoreactions are increased. Determination of peripheral blood T cell subsets and immunoglobulin in patients with ovarian cancer might be of some significance in the diagnosis of the state of the ovarian cancers,evaluation the prognosis and the state of immunity in organism.
出处 《标记免疫分析与临床》 CAS 2016年第2期174-176,共3页 Labeled Immunoassays and Clinical Medicine
关键词 卵巢癌 T淋巴细胞亚群 免疫球蛋白 Ovarian cancer T-Lymphocyte subsets Immunoglobulin
  • 相关文献

参考文献7

  • 1李阳敏,毛熙光.卵巢癌早期诊断与治疗新进展[J].西南军医,2008,10(5):106-108. 被引量:10
  • 2王静.化疗对卵巢癌患者外周血淋巴细胞亚群的影响[J].实用肿瘤学杂志,2013,27(6):539-542. 被引量:3
  • 3Babbage G, Ottensmeier C H, Blaydes J, et al. Immunoglobulin heavey chain locus events and sxpression of activation-lnduced cytldlne deaminase in epithelialbresat cancer cell lines. Cancer Res, 2006,66 ( 8 ) :3996-4000.
  • 4马宇毅.晚期卵巢癌新辅助化疗疗效分析[J].实用癌症杂志,2008,23(1):53-55. 被引量:14
  • 5Li Y, Geng S, Yin Q, et al. Decreased level of recent thymic emigrants in CD4 + and CD8 + T cells from CML patients. J Transl Med,2010,8 (3) :47-48.
  • 6Yasutomo K. The cellular an of CD4 +/ CD8 + lineage commitment. J Med Invest, 2002, 49(1-2) : 1-6.
  • 7Khazaie K, yon Boehmer H. The impact of CD4 + CD25 + Tregon tumor specific CD8 + T cell cytotoxicity and cancer. Semin Cancer Biol, 2006,16(2) : 124-126.

二级参考文献18

  • 1刘恩令,糜若然.卵巢癌的新辅助化疗[J].国外医学(妇产科学分册),2004,31(3):191-193. 被引量:1
  • 2赵晓东,张毅.晚期卵巢上皮癌新辅助化疗[J].国外医学(肿瘤学分册),2005,32(4):310-313. 被引量:7
  • 3张慧敏.晚期卵巢癌新辅助化疗与常规辅助化疗结果比较[J].中国综合临床,2005,21(11):1016-1018. 被引量:5
  • 4梅琳琳,岳天孚.晚期卵巢癌的新辅助化疗[J].国外医学(计划生育.生殖健康分册),2006,25(6):336-339. 被引量:10
  • 5Boente MP,Chids,HosKins WJ.The roles of surgery in the managerment of ovarian cancer primary and interval cytoreductive surgery[J].Semin in Oncol,1998,25:326.
  • 6Kuhn W,Rutke S,Spathe K,et al.Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in international Federation of Gynecology and Obstetrics StageⅢ ovarian carcinoma[J].Cancer,2001,92(12):2585.
  • 7Eddy Cotte,Olivier Glehen,Faheez Mohamed,Franck Lamy,Claire Falandry,Fran?ois Golfier,Francois Noel Gilly. Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients[J] 2007,World Journal of Surgery(9):1813~1820
  • 8Miodrag Milojkovic,Zlatko Hrgovic,Igor Hrgovic,Walter Jonat,Nicolai Maass,Damir Bukovi?. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis[J] 2004,Archives of Gynecology and Obstetrics(3):176~180
  • 9Torpy JM,Burke AE,Golub RM. JAMA patient page.Ovari-an cancer[J].{H}JAMA:the Journal of the American Medical Association,2011,(23):2484.
  • 10Ware Miller R,Smith A,Desimone CP. Performance of the American college of obstetricians and gynecologists′o-varian tumor referral guidelines with a multivariate index as-say[J].{H}OBSTETRICS AND GYNECOLOGY,2011,(06):1298-1306.

共引文献24

同被引文献151

引证文献16

二级引证文献117

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部